| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
127,470,000 |
| Market
Cap: |
1.95(B) |
| Last
Volume: |
875,937 |
Avg
Vol: |
1,084,799 |
| 52
Week Range: |
$11.665 - $20.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
8,699 |
11,368 |
11,368 |
11,368 |
| Total Sell Value |
$136,292 |
$185,375 |
$185,375 |
$185,375 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
2 |
3 |
3 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jones Steven C |
Director |
– • – |
2020-12-04 |
4 |
S |
$48.07 |
$3,095,420 |
I/I |
(64,394) |
1,115,658 |
|
-3% |
|
| Johnson Kevin C |
Director |
– • – |
2020-12-04 |
4 |
S |
$47.88 |
$1,181,822 |
D/D |
(24,683) |
30,983 |
|
-3% |
|
| Jones Steven C |
Director |
– • – |
2020-12-03 |
4 |
S |
$48.03 |
$958,102 |
I/I |
(19,948) |
1,180,052 |
|
-3% |
|
| Bonello William |
President, Informatics |
• – – |
2020-12-02 |
4 |
S |
$46.80 |
$374,400 |
D/D |
(8,000) |
12,060 |
|
-4% |
|
| Bonello William |
President, Informatics |
• – – |
2020-12-02 |
4 |
OE |
$8.03 |
$64,240 |
D/D |
8,000 |
20,060 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2020-11-25 |
4 |
S |
$45.48 |
$3,505,326 |
D/D |
(77,074) |
370,902 |
|
-5% |
|
| Cardoza George |
President, Pharma Services |
• – – |
2020-11-25 |
4 |
OE |
$7.52 |
$579,596 |
D/D |
77,074 |
447,976 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2020-11-24 |
4 |
S |
$45.19 |
$2,391,726 |
D/D |
(52,926) |
370,902 |
|
-4% |
|
| Cardoza George |
President, Pharma Services |
• – – |
2020-11-24 |
4 |
OE |
$7.52 |
$548,404 |
D/D |
72,926 |
423,828 |
|
- |
|
| Hipp Raymond R |
Director |
– • – |
2020-11-16 |
4 |
S |
$42.28 |
$2,959,600 |
D/D |
(70,000) |
66,800 |
|
-2% |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-11-16 |
4 |
S |
$42.34 |
$4,234,000 |
D/D |
(100,000) |
2,422,790 |
|
-2% |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-11-16 |
4 |
OE |
$7.52 |
$150,400 |
D/D |
20,000 |
2,522,790 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-11-13 |
4 |
S |
$41.56 |
$4,935,333 |
D/D |
(118,752) |
2,502,790 |
|
-11% |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-11-13 |
4 |
OE |
$7.52 |
$2,697,815 |
D/D |
358,752 |
2,621,542 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-11-12 |
4 |
S |
$42.18 |
$5,114,241 |
D/D |
(121,248) |
2,262,790 |
|
-12% |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-11-12 |
4 |
OE |
$7.52 |
$911,785 |
D/D |
121,248 |
2,384,038 |
|
- |
|
| Pedulla Denise E |
General Counsel |
• – – |
2020-11-10 |
4 |
S |
$42.00 |
$95,004 |
D/D |
(2,262) |
56,726 |
|
-14% |
|
| Pedulla Denise E |
General Counsel |
• – – |
2020-11-10 |
4 |
OE |
$7.85 |
$117,750 |
D/D |
15,000 |
58,988 |
|
- |
|
| Jones Steven C |
Director |
– • – |
2020-09-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
72,932 |
|
- |
|
| Jones Steven C |
Director |
– • – |
2020-09-29 |
4 |
S |
$36.55 |
$2,960,550 |
D/D |
(81,000) |
97,932 |
|
-58% |
|
| Jones Steven C |
Director |
– • – |
2020-09-29 |
4 |
S |
$36.95 |
$5,211,761 |
I/I |
(141,049) |
1,200,000 |
|
-58% |
|
| Jones Steven C |
Director |
– • – |
2020-09-28 |
4 |
S |
$36.56 |
$694,640 |
D/D |
(19,000) |
178,932 |
|
-58% |
|
| Jones Steven C |
Director |
– • – |
2020-09-28 |
4 |
S |
$36.34 |
$1,415,479 |
I/I |
(38,951) |
1,341,049 |
|
-58% |
|
| Crowther Bruce K |
Director |
– • – |
2020-09-24 |
4 |
S |
$35.01 |
$291,738 |
D/D |
(8,333) |
46,483 |
|
-57% |
|
| Crowther Bruce K |
Director |
– • – |
2020-09-24 |
4 |
OE |
$9.11 |
$75,914 |
D/D |
8,333 |
54,816 |
|
- |
|
431 Records found
|
|
Page 6 of 18 |
|
|
0.58 (3.94%) 
